ingredient Eltrombopag 50 mg
substitutes Elbonix 50 mg 7s x 5,Revolade 50mg 7s x 2 (FR)
treatment HCV infection
Shipping class Room Temperature
Medicine Overview by Anukar Pharmacy
( Elbonix 50mg 7s x 4 (28), Beacon )
TreatmentEltrombopag is used for low platelet count due to ITP or HCV infection. It is used to treat low platelet count due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. It’s also used to treat severe aplastic anemia.
Side EffectsNausea, Diarrhoea, Upper respiratory tract infection, Vomiting, Increased liver enzymes, Muscle pain, Urinary tract infection
Method of UseTake Eltrombopag on an empty stomach, either 1 hour before or 2 hours after meals.
How Elbonix 50mg 7s x 4 (28), Beacon WorksEltrombopag is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. Platelets help to reduce or prevent bleeding.
More Info by Anukar Pharmacy
( Elbonix 50mg 7s x 4 (28), Beacon )
Suggestions
- Take Eltrombopag at least 2 hours before or 4 hours after eating dairy products and calcium-fortified juices.
Warning by Anukar Pharmacy
( Elbonix 50mg 7s x 4 (28), Beacon )
Special precautions for Elbonix 50mg 7s x 4 (28), Beacon Heads up
| aspect | highlight | details |
|---|---|---|
Alcohol
|
WEIGH RISKS VS BENEFITS | Take Eltrombopag at least 2 hours before or 4 hours after eating dairy products and calcium-fortified juices. |
Pregnancy
|
WEIGH RISKS VS BENEFITS | There are no adequate and well-controlled studies of Eltrombopag use in pregnancy. In animal reproduction and developmental toxicity studies, there was evidence ofembryolethality and reduced fetal weights at maternally toxic doses. Eltrombopag should beused in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. |
Lactation
|
It is not known whether Eltrombopag is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Eltrombopag, a decision should be made whether to discontinue nursing or to discontinue Eltrombopag taking into account the importance of Eltrombopag to the mother. | |
Driving
|
There is no adequate data. Please consult your doctor. | |
Kidney
|
Hepatic impairment influences the exposure of Eltrombopag. Reduce the initial dose of Eltrombopag in patients with chronic ITP (adult and pediatric patients 6 years and older only) or severe aplastic anemia who also have hepatic impairment (Child-Pugh Class A, B, C). No dosage adjustment is necessary for patients with chronic hepatitis C and hepatic impairment. | |
Liver
|
No adjustment in the initial dose of Eltrombopag is needed for patients with renal impairment. Closely monitor patients with impaired renal function when administering Eltrombopag. |
Suggestion by Anukar Pharmacy on missing a dose
( Elbonix 50mg 7s x 4 (28), Beacon )
In case you miss a dose, take the next dose at the next time interval.
Disclaimer
The information of Anukar Pharmacy is for reference purpose only, and Anukar Pharmacy or Anukar Pharmacy or Anukar Pharmacy is not intended to be a replacement of professional medical advice, diagnosis, or treatment. Anukar Pharmacy suggest to ask the advice of a physician or any qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of anything you have learned from Anukar Pharmacy.
| 药名 | 艾曲泊帕 |
| 厂家 | 碧康制药 |
| 成分 | Eltrombopag50mg |
| 说明 |
艾曲波帕
艾曲波帕由英国葛兰素史克公司研发并于2008年11月获得美国FDA批准在美国上市。艾曲波帕是一种促血小板生成素受体激动剂适用于治疗慢性免疫性血小板减少性紫癜患者的血小板减少，
治疗作用：艾曲波帕是一种促血小板生成素受体激动剂适用于治疗慢性免疫性血小板减少性紫癜患者的血小板减少，对皮质激素、免疫球蛋白或脾切除反应不佳的患者。 艾曲波帕只应用于有ITP其血小板减少程度和临床情况增加出血风险的患者，不应用于意向正常血小板计数正常化。 艾曲波帕还可用于慢性丙型肝炎（CHC）患者血小板减少症的治疗，以便启动并维持以干扰素为基础的肝病标准疗法。
|
* 以上中文信息由印度阿努卡药房收集的Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）中文网络信息和软件翻译获得，阿努卡药房认为Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）中文产品介绍信息存在与Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）实际数据不一致的可能。阿努卡药房请用户把Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）页面数据作为参考。印度阿努卡药房建议用户在实际使用Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）数据或者信息时，以Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）制造商公开发布的Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）商品信息为参考。使用方法，以用户医生建议使用Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）决定为参考。用户任何关于Elbonix 50mg 28 Tablets, Beacon（艾曲泊帕）的建议，可以通知印度阿努卡药房，或通知阿努卡在线客服人员。谢谢
